Stay updated with breaking news from Blake Aftab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in...
22.04.2024 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data ... Seite 1
ADI-270 includes Adicet’s proprietary armoring technology and enhancements designed for improved persistence and durability within a solid tumor microenvironment ADI-270 demonstrated potent... | May 18, 2023
Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will retire at the end of the year, following the lead of CEO Alex Gorsky, who also departs soon. Emile Nuwaysir led Bayer's $1 billion bet on Parkinson's disease, and now he heads up gene therapy biotech Ensoma. Genentech's early cancer research leader Shiva Malek jumps to Novartis' NIBR oncology unit.
Published: Apr 13, 2021 MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will lead Adicet’s research group and will further develop existing and new opportunities for the Company’s gamma delta T cell platform. “We are very excited to have Blake join Adicet, and lead our research team as we advance the clinical developm...